Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more
Context Therapeutics Inc (CNTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.090x
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has a cash flow conversion efficiency ratio of -0.090x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.58 Million) by net assets ($73.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Context Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Context Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Context Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Context Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adira Dinamika Multi Finance
JK:ADMF
|
0.067x |
|
Pacific Textiles Holdings Limited
PINK:PTEXF
|
N/A |
|
Hangzhou Heatwell Electric Heating Technology Co., Ltd.
SHG:603075
|
0.062x |
|
Beijing Bohui Science & Technology Co Ltd
SHG:688004
|
-0.017x |
|
Sligro Food Group N.V.
PINK:SIGRF
|
0.059x |
|
NationGate Holdings Berhad
KLSE:0270
|
0.091x |
|
Zalaris ASA
OL:ZAL
|
0.250x |
|
Jiangsu United Water Technology Co. Ltd. Cl A
SHG:603291
|
N/A |
Annual Cash Flow Conversion Efficiency for Context Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Context Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $95.27 Million | $-14.56 Million | -0.153x | +91.38% |
| 2023-12-31 | $11.87 Million | $-21.05 Million | -1.773x | -354.84% |
| 2022-12-31 | $34.76 Million | $-13.55 Million | -0.390x | -113.84% |
| 2021-12-31 | $48.27 Million | $-8.80 Million | -0.182x | -398.13% |
| 2020-12-31 | $-16.92 Million | $-1.03 Million | 0.061x | -48.34% |
| 2019-12-31 | $-23.96 Million | $-2.84 Million | 0.118x | +131.22% |
| 2017-12-31 | $58.95 Million | $-22.35 Million | -0.379x | +83.73% |
| 2016-12-31 | $13.12 Million | $-30.57 Million | -2.331x | -- |